pdf   xlsx method abbreviations

mNSCLC - L2 - PDL1 positive, immune chekpoint inhibitors , meta-analysis of study results

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths (OS) 0.79 [0.68, 0.93]< 124%3 studies (3/-)99.8 %some concernnot evaluable moderatecrucial-
progression or deaths (PFS) 0.89 [0.76, 1.03]< 122%3 studies (3/-)93.9 %some concernnot evaluable moderateimportant-
DOR 9.61 [3.07, 30.08]< 10%1 study (1/-)0.0 %NAnot evaluable non important-
objective responses (ORR) 1.84 [1.17, 2.88]> 148%3 studies (3/-)99.6 %some concernnot evaluable moderatenon important-

safety endpoints 00

AE (any grade) 0.24 [0.01, 5.43]< 10%1 study (1/-)81.2 %NAnot evaluable non important-
AE (grade 3-4) 0.36 [0.18, 0.75]< 10%1 study (1/-)99.7 %NAnot evaluable non important-
AE leading to death (grade 5) 3.27 [0.63, 16.86]< 10%1 study (1/-)7.9 %NAnot evaluable non important-
AE leading to treatment discontinuation (any grade) 0.63 [0.24, 1.67]< 10%1 study (1/-)82.4 %NAnot evaluable non important-
SAE (any grade) 1.73 [0.81, 3.73]< 10%1 study (1/-)8.0 %NAnot evaluable non important-
STRAE (any grade) 1.02 [0.33, 3.10]< 10%1 study (1/-)48.7 %NAnot evaluable non important-
TRAE (any grade) 0.19 [0.08, 0.46]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE (grade 3-4) 0.13 [0.05, 0.36]< 10%1 study (1/-)100.0 %NAnot evaluable non important-
TRAE leading to death (grade 5) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
TRAE leading to discontinuation (any grade) 1.02 [0.24, 4.26]< 10%1 study (1/-)49.1 %NAnot evaluable non important-

TRAE (grade 3-4) endpoints 00

Acute kidney injury TRAE (grade 3-4) 2.05 [0.07, 62.21]< 10%1 study (1/-)34.2 %NAnot evaluable non important-
Adrenal insufficiency TRAE (grade 3-4) 2.05 [0.07, 62.21]< 10%1 study (1/-)34.2 %NAnot evaluable non important-
Anaemia TRAE (grade 3-4) 0.08 [0.00, 1.41]< 10%1 study (1/-)95.6 %NAnot evaluable non important-
Asthenia TRAE (grade 3-4) 0.25 [0.01, 5.61]< 10%1 study (1/-)80.7 %NAnot evaluable non important-
Colitis TRAE (grade 3-4) 2.05 [0.07, 62.21]< 10%1 study (1/-)34.2 %NAnot evaluable non important-
Constipation TRAE (grade 3-4) 0.50 [0.02, 15.30]< 10%1 study (1/-)65.1 %NAnot evaluable non important-
Decreased appetite TRAE (grade 3-4) 0.50 [0.02, 15.30]< 10%1 study (1/-)65.1 %NAnot evaluable non important-
Dermatitis acneiform TRAE (grade 3-4) 0.50 [0.02, 15.30]< 10%1 study (1/-)65.1 %NAnot evaluable non important-
Diarrhoea TRAE (grade 3-4) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Dyspepsia TRAE (grade 3-4) 0.50 [0.02, 15.30]< 10%1 study (1/-)65.1 %NAnot evaluable non important-
Fatigue TRAE (grade 3-4) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Febrile neutropenia TRAE (grade 3-4) 0.08 [0.00, 1.41]< 10%1 study (1/-)95.6 %NAnot evaluable non important-
Hepatitis TRAE (grade 3-4) 2.05 [0.07, 62.21]< 10%1 study (1/-)34.2 %NAnot evaluable non important-
Hyperthyroidism TRAE (grade 3-4) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Hypothyroidism TRAE (grade 3-4) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Increased lipase level TRAE (grade 3-4) 2.05 [0.07, 62.21]< 10%1 study (1/-)34.2 %NAnot evaluable non important-
Infusion-related reactions TRAE (grade 3-4) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Leucopenia TRAE (grade 3-4) 0.16 [0.01, 3.32]< 10%1 study (1/-)87.8 %NAnot evaluable non important-
Nausea TRAE (grade 3-4) 0.25 [0.01, 5.61]< 10%1 study (1/-)80.7 %NAnot evaluable non important-
Neutropenia TRAE (grade 3-4) 0.09 [0.01, 1.76]< 10%1 study (1/-)94.1 %NAnot evaluable non important-
Pneumonia TRAE (grade 3-4) 1.02 [0.06, 16.62]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Pneumonitis TRAE (grade 3-4) 1.02 [0.02, 52.03]< 10%1 study (1/-)49.7 %NAnot evaluable non important-
Rash TRAE (grade 3-4) 1.02 [0.06, 16.62]< 10%1 study (1/-)49.5 %NAnot evaluable non important-
Stomatitis TRAE (grade 3-4) 2.05 [0.07, 62.21]< 10%1 study (1/-)34.2 %NAnot evaluable non important-

AE (grade 3-4) endpoints 00

LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias; suggested: nominally statistically significant but without a strict control of overall risk of type 1 error; inconclusive: not nominally statistically significant; safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



 

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons